A real-world study of Australian and New Zealand patients concludes that infliximab and adalimumab have similar efficacy in Crohn’s disease. However the observational four-year study found infliximab required a concomitant immunomodulator in order to maintain an optimal response compared to adalimumab monotherapy. According to the authors led by Associate Professor Graham Radford-Smith, group leader of the ...
Infliximab and adalimumab have similar efficacy in Crohn’s
By Mardi Chapman
1 Mar 2017